The Latest Breaking News from FDA

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59.

These smaller innovators are quietly advancing promising therapies that could unlock their true potential.

The FDA recalls over 140,000 bottles of Atorvastatin after failed quality tests. Find out which products are affected and what patients should do next.

Lynkuet was approved by the FDA Friday to treat moderate-to-severe hot flashes and night sweats

The tablets were distributed nationwide in up to 1,000-count bottles

On Friday, Biogen Inc. (NASDAQ:BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthens Biogen's immunology.

Sanofi SA (NASDAQ:SNY) reported third-quarter sales of $14.55 billion (12.43 billion euros), beating the consensus of $14.46 billion. Sales increased 2.3% year over year, up 7% in constant currency.

On Friday, the U.S. Food and Drug Administration (FDA) approved GSK Plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy.

Every time you see the words “FDA approved,” it’s supposed to mean safety, science, and trust. After all, the Food and Drug Administration is the final checkpoint before a product reaches your medicine cabinet, right? But history says otherwise. Over the years, some truly shocking—and sometimes disastrous—products have slipped through…